COLO 201 Xenograft Model Service for Colon Cancer

COLO 201 Xenograft Model Service for Colon Cancer --- a robust preclinical platform for evaluating therapeutic efficacy against well-differentiated colorectal adenocarcinoma. Alfa Cytology delivers validated COLO 201 xenograft models with reproducible tumor growth kinetics and comprehensive endpoint analysis, enabling rapid progression from candidate screening to IND-enabling pharmacology studies.

Overview of COLO 201 Xenograft Model for Colon Cancer

COLO 201 is a human colorectal adenocarcinoma cell line originally established in 1975 from the ascitic fluid of a 70-year-old Caucasian male patient with Dukes' type D (metastatic) colon cancer. Unlike many epithelial colon cancer lines derived from solid primary tumors, COLO 201 was isolated from a metastatic site, conferring distinct biological properties including fibroblast-like bipolar morphology, predominant suspension growth, and high tumorigenic potential. The cell line exhibits a hypertriploid karyotype (modal chromosome number 71--78) with 10--11 marker chromosomes, and carries key oncogenic driver mutations including heterozygous BRAF V600E, APC truncating mutation, and homozygous CTNNB1 mutation, placing it within the canonical WNT/beta-catenin and MAPK signaling pathways characteristic of colorectal carcinogenesis. COLO 201 is microsatellite stable (MSS) and negative for classical colon tumor markers CEA and CSAp, making it particularly valuable for studying tumor biology independent of CEA-driven mechanisms.

In xenograft applications, COLO 201 demonstrates exceptional engraftment efficiency, achieving 100% tumor take in immunodeficient nude mice within 21 days following subcutaneous or intraperitoneal inoculation of 10^7 cells. The resulting tumors form glandular structures histologically resembling human adenocarcinoma, providing a physiologically relevant platform for preclinical drug evaluation. The cell line's CD44-positive subpopulation exhibits cancer stem cell behavior, including enhanced tumorigenicity and resistance to 5-fluorouracil, enabling studies on tumor heterogeneity and therapeutic resistance. COLO 201 xenografts have been extensively utilized in toxicology screening, chemotherapeutic efficacy assessment, 3D spheroid model development, and mechanistic investigations of flavonoid-induced apoptosis, establishing it as a versatile and well-characterized model for gastrointestinal oncology research.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through WNT/beta-catenin and MAPK signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for CD44-positive cancer stem cell subpopulations.

Figure 1. Three colorectal cancer cell (CRC) lines had a CD44+ population. (Okuyama, H, et al., 2020)

Cell Line Information: COLO 201

The COLO 201 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its derivation from a metastatic site, distinct fibroblast-like morphology, and CD44-positive cancer stem cell subpopulation make it unique among available colon cancer cell lines and essential for preclinical research targeting metastatic colorectal carcinoma.

Our Services

Alfa Cytology leverages its deep expertise in preclinical tumor modeling to provide validated COLO 201 xenograft models with stringent quality control, reproducible tumor growth parameters, and flexible study designs tailored to your compound's development stage --- from early pharmacology screening to comprehensive IND-enabling efficacy and safety packages.

Workflow of COLO 201 Xenograft Model Construction

Alfa Cytology follows a standardized, GLP-compliant workflow to construct COLO 201 xenograft models, ensuring consistent tumor engraftment, measurable growth kinetics, and reliable pharmacological readouts across all studies. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Expansion: COLO 201 cells are authenticated by STR profiling against the reference database (ATCC CCL-224) and expanded under optimized RPMI 1640 + 10% FBS conditions. Mycoplasma, bacteria, and fungi screening is performed prior to inoculation.
2. Recipient Animal Preparation: Female BALB/c nude mice (6--8 weeks, 18--22 g) are acclimatized for 7 days under specific pathogen-free (SPF) conditions with a 12-hour light/dark cycle and ad libitum access to sterilized food and water.
3. Tumor Cell Inoculation: Exponentially growing COLO 201 cells are harvested, viability confirmed (>95% by trypan blue exclusion), and resuspended in serum-free RPMI 1640 mixed 1:1 with Matrigel. A cell suspension of 1x10^7 cells in 100--200 uL is injected subcutaneously into the right flank of each mouse.
4. Tumor Monitoring and Randomization: Tumor volumes are measured twice weekly using digital calipers (V = 0.5 x L x W^2). Upon reaching a mean tumor volume of 80--150 mm^3, animals are randomized into treatment groups (n=8--10 per group) to ensure balanced baseline tumor burden.
5. Compound Administration and Efficacy Assessment: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Tumor growth inhibition (TGI), body weight, and clinical signs are monitored throughout the treatment period.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tissue samples are fixed in 10% neutral buffered formalin for histopathology (H&E, IHC), snap-frozen in liquid nitrogen for molecular analysis, or processed for flow cytometry and biomarker quantification.

Figure 2: Schematic workflow illustrating the derivation and construction of the COLO 201 Xenograft Model at Alfa Cytology.

Case Study-COLO 201 Xenograft Model Development

Alfa Cytology has successfully established and validated the COLO 201 subcutaneous xenograft model with robust tumor growth kinetics and consistent pharmacological responses. In a representative efficacy study, COLO 201 tumors demonstrated reliable engraftment across all animals with measurable growth curves suitable for evaluating novel antitumor agents, including targeted therapies and cytotoxic compounds. Detailed tumor growth inhibition data, pharmacokinetic correlations, and histopathological analyses are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology combines rigorous scientific methodology with operational flexibility to deliver COLO 201 xenograft models that accelerate your preclinical development timeline.

• Verified Cell Line Integrity: Validated cell line authentication by STR profiling and comprehensive pathogen screening ensures model integrity from the start.
• High Take Rates and Consistency: Standardized tumor inoculation protocols achieve >95% engraftment rates with reproducible growth kinetics across independent studies.
• Comprehensive Analytical Support: Flexible study designs accommodate subcutaneous, orthotopic, and metastatic model configurations tailored to your therapeutic hypothesis.
• Tailored Study Designs: Comprehensive endpoint analysis including tumor growth inhibition, body weight monitoring, histopathology, IHC, and molecular biomarker quantification.
• Standardized Protocols: GLP-compliant data packages and detailed study reports support seamless transition from pharmacology screening to IND-enabling toxicology programs.
• Dedicated Project Management: Dedicated project management with rapid study initiation and real-time data access through our secure client portal.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated COLO 201 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, or schedule a consultation with our preclinical oncology team. Please reach out to us today via our inquiry form or email to learn more about our COLO 201 Xenograft Model services.

For research use only. Not intended for any clinical use.